Quick Answer
CRESCENT BIOPHARMA, INC. reported Operating Income Loss of -$152.63 million for the year ending 2025.
- CRESCENT BIOPHARMA, INC. showed a decrease of -281.2% in Operating Income Loss from 2024 to 2025.
- This data is from CRESCENT BIOPHARMA, INC.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2012 to 2025), CRESCENT BIOPHARMA, INC.'s Operating Income Loss has declined by 4,298.9%.
- Historical annual values: Fiscal year 2025: -$152.63 million | Fiscal year 2024: -$40.04 million | Fiscal year 2023: -$39.28 million | Fiscal year 2022: -$47.40 million | Fiscal year 2021: -$63.45 million | Fiscal year 2020: -$51.51 million | Fiscal year 2019: -$61.39 million | Fiscal year 2018: -$51.50 million | Fiscal year 2017: -$33.93 million | Fiscal year 2016: -$31.91 million | Fiscal year 2015: -$12.78 million | Fiscal year 2014: -$11.14 million | Fiscal year 2013: -$10.61 million | Fiscal year 2012: $3.64 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: